FF
DSGN icon

FourThought Financial’s Design Therapeutics DSGN Stock Holding History

FourThought Financial’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1K Hold
44
– – ﹤0.01% 1398
2022
Q2 		$1K Buy
+44
New +$594 ﹤0.01% 1392

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FourThought Financial's DSGN Position: Q3 2022 in Review

FourThought Financial held its Design Therapeutics (DSGN) position steady in Q3 2022 at 44 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1398.

FourThought Financial first reported a position in DSGN in Q2 2022 and has held it in 2 quarters since. 79 funds tracked by Wall St. Rank hold DSGN as of Q3 2022.

  • FourThought Financial held 44 shares of Design Therapeutics worth $1K as of Q3 2022.
  • FourThought Financial left its Design Therapeutics share count unchanged in Q3 2022.
  • Design Therapeutics made up ﹤0.01% of FourThought Financial's portfolio in Q3 2022, its #1398 holding.
  • FourThought Financial first reported a position in Design Therapeutics in Q2 2022 and has held it in 2 quarters since.
  • 79 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.